己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯 | 9004-78-8

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 消毒防腐药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯
• 中文别名: 2-苯氧乙醇；苯氧乙醇；乙二醇一苯醚；二苯氧乙醇；2-苯氧基乙醇；苯氧基乙醇；β-羟乙基苯基醚；苯酚聚氧乙烯醚；乙二醇苯醚；乙二醇苯基醚；苯基溶纤剂；乙二醇单苯醚；1-羟基-2-苯氧基乙烷
• 英文名称: 2-Phenoxyethanol
• 英文别名: phenoxyethanol；2-phenoxyethan-1-ol
• CAS: 9004-78-8；122-99-6
• 化学式: C₈H₁₀O₂
• mdl: MFCD00002857
• 分子量: 138.166
• InChiKey: QCDWFXQBSFUVSP-UHFFFAOYSA-N

物化性质

• 熔点：
  11-13 °C (lit.)
• 沸点：
  247 °C (lit.)
• 密度：
  1.102 g/mL at 25 °C (lit.)
• 蒸气密度：
  4.8 (vs air)
• 闪点：
  >230 °F
• 溶解度：
  可溶、透明、无色至微黄色
• LogP：
  1.2 at 23℃
• 物理描述：
  Ethylene glycol phenyl ether is a colorless liquid with a pleasant odor. Density 1.02 g / cm3. An irritant.
• 颜色/状态：
  Oily liquid
• 气味：
  Faint aromatic odor
• 味道：
  Burning taste
• 蒸汽密度：
  4.77 (NTP, 1992) (Relative to Air)
• 蒸汽压力：
  0.007 mm Hg at 25 °C
• 稳定性/保质期：
  STABLE IN PRESENCE OF ACIDS & ALKALIES.
• 自燃温度：
  500 °C
• 分解：
  When heated to decomposition it emits acrid smoke and irritating fumes.
• 粘度：
  20.5 centistokes at 25 °C
• 燃烧热：
  958 kcal/mole
• 表面张力：
  42.0 dynes/cm
• 折光率：
  Index of refraction: 1.534 at 20 °C/D
• 解离常数：
  pKa = 15.10 at 25 °C
• 相对蒸发率：
  < 0.01 (Butyl acetate = 1.0)
• 保留指数：
  1191.6;1186;1210;1214;1213;1204.2;1187.1;1189;1185;1194

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

已对大鼠和人体内苯氧乙醇的命运进行了研究。肠道吸收速率很快，3小时内在排泄物中检测到60-70%的(14)C，在第一天内检测到>95%的总4天尿(14)C。在粪便中检测到微量的放射性。给药四天后，仅在尸体中检测到微量的放射性，主要在肝脏(<剂量的0.2%)、脂肪和肌肉中。在第四天，血液中的(14)C浓度仅为0.001。苯氧乙醇的主要代谢物是苯氧乙酸。

The fate of phenoxyethanol in rats and humans has been investigated. The rate of intestinal absorption was rapid, with 60-70% of the excreted (14)C detected at 3 hours and > 95% of the total 4-day urinary (14)C detected within the first 24 hr. Trace amounts of radioactivity were detected in feces. Four days after dosing, only trace amounts of radioactivity remained in the carcass, primarily in the liver (< 0.2% of the dose), fat and muscle. At the 4 day point, the (14)C concentration in blood was measured to be only 0.001. The major metabolite of phenoxyethanol is phenoxyacetic acid.

来源:DrugBank

代谢

一旦水解，2-苯氧乙醇就会迅速被吸收并氧化成苯氧乙酸...

Once hydrolyzed, 2-phenoxyethanol is rapidly absorbed and oxidized to phenoxyacetic acid ...

来源:Hazardous Substances Data Bank (HSDB)

代谢

在锥形杯菌、侧耳菌和多变拟迷孔菌中产生苯酚……来自表格/

YIELDS PHENOL IN CONIOPHORA, IN PLEUROTUS, & IN POLYSTICTUS ... . /FROM TABLE/

来源:Hazardous Substances Data Bank (HSDB)

代谢

乙二醇醚的毒性与其通过细胞质醇脱氢酶（ADH；EC 1.1.1.1）和醛脱氢酶（ALDH；1.2.1.3）氧化为相应的醛和甲酸有关。这些化合物的皮肤接触可能导致局部或全身毒性，包括皮肤致敏和刺激、生殖、发育和血液学效应。以前的研究表明，皮肤具有局部代谢施用化学物质的能力。因此，在人类的风险评估中，需要考虑这些化合物经皮吸收过程中的代谢。通过差速离心法从大鼠肝脏、全层皮肤和经皮皮肤中制备细胞质组分。在大鼠皮肤多次接触地塞米松、乙醇或2-丁氧基乙醇（2-BE）后，也制备了细胞质组分。通过紫外分光光度法连续监测这些组分中ADH/ALDH将乙醇、2-乙氧基乙醇（2-EE）、乙二醇、2-苯氧基乙醇（2-PE）和2-BE转化为甲酸的速度，通过340 nm处NAD+到NADH的转化。大鼠肝脏细胞质中ADH氧化速率以乙醇最高，其次是2-EE >乙二醇 >2-PE >2-BE。然而，使用全层和经皮大鼠皮肤细胞质组分时，代谢顺序变为2-BE >2-PE >乙二醇 >2-EE >乙醇，经皮皮肤细胞质的特异活性大约是全层大鼠皮肤的兩倍。这表明ADH和ALDH定位于表皮，表皮在经皮皮肤细胞质中的蛋白质含量比全层皮肤细胞质多。在大鼠肝脏细胞质中，吡唑对ADH氧化的抑制程度以乙醇最高，其次是2-EE >乙二醇 >2-PE >2-BE，但在皮肤细胞质中，它仅抑制了40%的乙醇代谢。双硫仑完全抑制了肝脏和皮肤细胞质组分中的醇和乙二醇醚代谢。尽管在大鼠肝脏中ADH1、ADH2和ADH3在蛋白质水平上表达，但只有ADH1和ADH2被吡唑选择性抑制，它们是优先代谢短链醇而不是中等链长醇的主要同种型。然而，在大鼠皮肤中，ADH1、ADH3和ADH4占主导地位，对吡唑的敏感性不同，负责代谢乙二醇醚。ALDH1是在大鼠肝脏和皮肤细胞质组分中占主导地位的同种型，被双硫仑选择性抑制，并响应这些组织中表达的ADH同种型形成的醛的量。因此，ADH和ALDH对不同碳链长度的醇和乙二醇醚的不同亲和力可能反映了在大鼠肝脏和皮肤中的相对同种型表达。在多次局部接触后，乙醇处理后乙醇代谢增加最多，2-BE处理后2-BE代谢增加最多。乙醇和2-BE可能诱导特定的ADH和ALDH同种型，这些同种型优先代谢短链醇（即ADH1、ALDH1）和较长链醇（即ADH3、ADH4、ALDH1）。使用地塞米松等一般诱导剂处理增强了乙醇和2-BE的代谢，这表明诱导了多种ADH同种型。

The toxicity of glycol ethers is associated with their oxidation to the corresponding aldehyde and alkoxyacetic acid by cytosolic alcohol dehydrogenase (ADH; EC 1.1.1.1.) and aldehyde dehydrogenase (ALDH; 1.2.1.3). Dermal exposure to these compounds can result in localised or systemic toxicity including skin sensitisation and irritancy, reproductive, developmental and hematological effects. It has previously been shown that skin has the capacity for local metabolism of applied chemicals. Therefore, there is a requirement to consider metabolism during dermal absorption of these compounds in risk assessment for humans. Cytosolic fractions were prepared from rat liver, and whole and dermatomed skin by differential centrifugation. Rat skin cytosolic fractions were also prepared following multiple dermal exposure to dexamethasone, ethanol or 2-butoxyethanol (2-BE). The rate of ethanol, 2-ethoxyethanol (2-EE), ethylene glycol, 2-phenoxyethanol (2-PE) and 2-BE conversion to alkoxyacetic acid by ADH/ALDH in these fractions was continuously monitored by UV spectrophotometry via the conversion of NAD+ to NADH at 340 nm. Rates of ADH oxidation by rat liver cytosol were greatest for ethanol followed by 2-EE >ethylene glycol >2-PE >2-BE. However, the order of metabolism changed to 2-BE >2-PE >ethylene glycol >2-EE >ethanol using whole and dermatomed rat skin cytosolic fractions, with approximately twice the specific activity in dermatomed skin cytosol relative to whole rat skin. This suggests that ADH and ALDH are localised in the epidermis that constitutes more of the protein in dermatomed skin than whole skin cytosol. Inhibition of ADH oxidation in rat liver cytosol by pyrazole was greatest for ethanol followed by 2-EE >ethylene glycol >2-PE >2-BE, but it only inhibited ethanol metabolism by 40% in skin cytosol. Disulfiram completely inhibited alcohol and glycol ether metabolism in the liver and skin cytosolic fractions. Although ADH1, ADH2 and ADH3 are expressed at the protein level in rat liver, only ADH1 and ADH2 are selectively inhibited by pyrazole and they constitute the predominant isoforms that metabolise short-chain alcohols in preference to intermediate chain-length alcohols. However, ADH1, ADH3 and ADH4 predominate in rat skin, demonstrate different sensitivities to pyrazole, and are responsible for metabolising glycol ethers. ALDH1 is the predominant isoform in rat liver and skin cytosolic fractions that is selectively inhibited by disulfiram and responds to the amount of aldehyde formed by the ADH isoforms expressed in these tissues. Thus, the different affinity of ADH and ALDH for alcohols and glycol ethers of different carbon-chain length may reflect the relative isoform expression in rat liver and skin. Following multiple topical exposure, ethanol metabolism increased the most following ethanol treatment, and 2-BE metabolism increased the most following 2-BE treatment. Ethanol and 2-BE may induce specific ADH and ALDH isoforms that preferentially metabolise short-chain alcohols (i.e. ADH1, ALDH1) and longer chain alcohols (i.e. ADH3, ADH4, ALDH1), respectively. Treatment with a general inducing agent such as dexamethasone enhanced ethanol and 2-BE metabolism suggesting induction of multiple ADH isoforms.

来源:Hazardous Substances Data Bank (HSDB)

代谢

进行了研究，以评估使用兔红细胞（RBC）的体外溶血潜力。苯氧乙酸（PAA）被识别为EGPE的主要血液代谢物。将雌性兔红细胞暴露于体外，表明EGPE的溶血性远大于PAA。

Studies were conducted... to evaluate the in vitro hemolytic potential of / ethylene glycol phenyl ether/ EGPE and its major metabolite using rabbit red blood cells (RBC). Phenoxyacetic acid (PAA) was identified as a major blood metabolite of EGPE. In vitro exposure of female rabbit erythrocytes indicated EGPE to be considerably more hemolytic than PAA.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 毒性总结

2-苯氧乙醇是一种乙二醇醚。乙二醇醚可以通过被醇脱氢酶（ADH；EC 1.1.1.1）和醛脱氢酶（ALDH；EC 1.2.1.3）分别氧化成相应的醛和醇基乙酸而产生毒性。（A15201）2-苯氧乙醇能减少NMDA诱导的膜电流，表明2-苯氧乙醇具有神经毒性潜力。（A15202）

2-Phenoxyethanol is a glycol ether. Glycol ethers can produce toxicity following oxidation to the corresponding aldehyde and alkoxyacetic acid by alcohol dehydrogenase (ADH; EC 1.1.1.1) and aldehyde dehydrogenase (ALDH; EC 1.2.1.3), respectively. (A15201) 2-Phenoxyethanol causes reduction of NMDA-induced membrane currents, indicating a neurotoxic potential for 2-phenoxyethanol. (A15202)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

表皮（A15201）；摄入

Dermal (A15201); ingestion

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 症状

可能会导致呕吐和腹泻。

May cause vomiting and diarrhea.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下），以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

• 消除途径

对大鼠和人体中苯氧乙醇的命运进行了研究。口服剂量为16、27或160 mg/kg体重的(2-(14)C)苯氧乙醇给雄性科沃斯大鼠后，24小时内通过尿液排出的量超过90%。一只雌性大鼠也在24小时内通过尿液排出了约90%的27 mg/kg体重剂量。从雌性和雄性大鼠的呼出空气中分别回收了约2%和1.3%的摄入剂量。

The fate of phenoxyethanol in rats and humans has been investigated. More than 90% of an oral dose of 16, 27 or 160 mg/kg body weight of (2-(14)C)phenoxyethanol administered to male Colworth rats by was excreted in the urine within 24 hours of administration. A female rat also excreted about 90% of a dose of 27 mg/kg body weight in the urine within 24 hours. About 2% and 1.3% of the ingested dose was recovered from the exhaled air of female and male rats, respectively.

来源:DrugBank

吸收、分配和排泄

• 分布容积

对苯氧乙醇的药代动力学研究使用了一种质谱模型，用于同时分析大鼠血浆、尿液和7种不同组织中苯氧乙醇（PE）及其主要代谢物苯氧乙酸（PAA）。苯氧乙醇的绝对局部生物利用度分别为乳剂75.4%和乳膏76.0%。PE转化为PAA的程度很高，乳剂和乳膏的平均AUCPAA-to-AUCPE比值分别为4.4和5.3。稳态下，肾脏、脾脏、心脏、大脑和睾丸的PE组织-血浆浓度比（Kp）高于1，而肺和肝脏的比值较低（0.6）；而代谢物Kp比值在肾脏、肝脏、肺和睾丸中较高，在其他组织中较低（0.3）。

A pharmacokinetic study of phenoxyethanol was performed using a mass spectrometry model for simultaneous analysis of phenoxyethanol (PE) and its major metabolite, phenoxyacetic acid (PAA), in rat plasma, urine, and 7 different tissues. The absolute topical bioavailability of PE was 75.4% and 76.0% for emulsion and lotion, respectively. Conversion of PE to PAA was extensive, with the average AUCPAA-to-AUCPE ratio being 4.4 and 5.3 for emulsion and lotion, respectively. The steady-state tissue-to-plasma PE concentration ratio (Kp) was higher than unity for kidney, spleen, heart, brain, and testis and was lower (0.6) for lung and liver, while the metabolite Kp ratio was higher than unity for kidney, liver, lung, and testis and was lower (0.3) for other tissues.

来源:DrugBank

吸收、分配和排泄

11毫克的未标记的2-苯氧乙醇在一次口服剂量后，在一个健康的男性志愿者尿液中以2-苯氧乙酸的形式被完全测定。大部分的酸是以未结合的形式被排泄的。

... An entire oral dose of 11 mg of unlabelled 2-phenoxyethanol was accounted for in the urine of one healthy male volunteer as 2-phenoxyacetic acid. Most of the acid was excreted unconjugated.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

2-苯氧乙醇在大鼠和人体内的命运已经得到了研究。给予雄性Colworth大鼠口服剂量为16、27或160 mg/kg bw的(2-(14)C)苯氧乙醇，超过90%的剂量在24小时内通过尿液排出。一只雌性大鼠也在24小时内通过尿液排出了约90%的27 mg/kg bw剂量。大约2%和1.3%的摄入剂量分别从雌性和雄性大鼠的呼出气体中恢复。肠道吸收速率很快，60-70%的排出(14)C在3小时内检测到，总4天尿液中超过95%的(14)C在前24小时内检测到。在粪便中检测到微量的放射性。给药4天后，仅在肝脏(<剂量的0.2%)、脂肪和肌肉中残留有微量放射性。在4天时，血液中的(14)C浓度仅为0.001。

The fate of 2-phenoxyethanol in rats and humans has been investigated. More than 90% of an oral dose of 16, 27 or 160 mg/kg bw of (2-(14)C)phenoxyethanol given to male Colworth rats by gavage was excreted in the urine within 24 hr. A female rat also excreted about 90% of a dose of 27 mg/kg bw in the urine within 24 hr. Approximately 2 and 1.3% of the ingested dose was recovered from expired air of female and male rats, respectively. The rate of intestinal absorption was rapid, with 60-70% of the excreted (14)C detected at 3 hr and > 95% of the total 4-day urinary (14)C detected within the first 24 hr. Trace amounts of radioactivity were detected in feces. Four days after dosing, only trace amounts of radioactivity remained in the carcass, primarily in the liver (< 0.2% of the dose), fat and muscle. At 4 days, the (14)C concentration in blood was only 0.001.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

... NOT READILY ABSORBED THROUGH THE SKIN IN ACUTELY TOXIC AMT. ... 不易通过皮肤吸收，尤其是在急性毒性剂量下。

... NOT READILY ABSORBED THROUGH THE SKIN IN ACUTELY TOXIC AMT.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• TSCA：
  Yes

制备方法与用途

苯氧乙醇

传统防腐剂

苯氧乙醇（Phenoxyethanol）是一种传统防腐剂，为无色稍带黏性的油状液体，具有轻微的芳香气味和火辣味。它微溶于水，基本不溶于矿物油，可与丙酮、乙醇和甘油任意混合。

苯氧乙醇对铜绿假单胞菌（绿脓杆菌）有显著杀灭效果，并能抑制革兰阳性菌及革兰阴性菌的生长。其机制是通过作用于细胞膜增大钾离子的透过率，降低酶活性，从而抑制细胞生长达到抗菌效果。单独使用苯氧乙醇时，低浓度下防腐效果不佳，高浓度又可能引起皮肤刺痛和灼热感，因此需要与其他防腐成分复配使用。

毒性

作为当前防腐剂标准的化合物之一，苯氧乙醇一般不会释放甲醛，相较于会释放甲醛的其他化合物，它是一个更优秀的替代品。根据《化妆品防腐剂的现状与发展》2007版数据显示，苯氧乙醇的大鼠经口半数致死量为3000 mg/kg，小鼠为4000 mg/kg，属于轻度毒性。

合成方法

采用苯酚一环氧乙烷法制备苯氧乙醇：在乙酸钠或氢氧化钠的作用下，苯酚与环氧乙烷缩合。反应后通过粗品减压蒸馏得成品，该工艺中苯酚转化率≥99%，合成收率≥95%，总产品收率达90%。反应方程式如下：

[ \text{Phenol} + \text{EO} \xrightarrow{\text{NaAc/H}_2\text{O}} \text{Phenoxyethanol} ]

此方法需在温度20 ℃和0.2―0.25 MPa的压力下进行，适合大规模工业生产。

化学性质

苯氧乙醇为无色液状液体。熔点14℃，沸点245.2℃。易溶于醇、醚及氢氧化钠溶液，微溶于水，在酸或碱中稳定，并具有芳香气味和烧灼味。

用途

苯氧乙醇是一种高沸点有机溶剂，可用于水性涂料及油墨成膜助剂、香料定香剂、油墨流畅剂、药用防腐杀菌剂、电子清洗剂及油墨慢干剂等。同时，它也具有良好的溶解性能，能与多种树脂如丙烯酸树脂、硝基纤维素、乙基纤维素、环氧树脂、醇酸树脂和苯氧基树脂等多种有机物混溶。

生产方法

由苯酚和环氧乙烷加成而得，在乙酸钠或氢氧化钠存在下反应。反应温度为200℃，压力为0.2-0.25 MPa。

参考资料

1. 周湘云,刘称心. 苯氧乙醇的性质、制备和应用[J]. 化工时刊, 1999(05):24-26.
2. 张亨. 苯氧乙醇的合成研究进展[J]. 化工中间体, 2013, 10(10):13-19.
3. 杨杰,李程碑. 乙基己基甘油与苯氧乙醇复配体的研究[J]. 广东化工, 2016, 43(02):55-56+58.
4. 廖子逸. 化妆品防腐保湿剂的应用进展及发展趋势[J]. 山东化工, 2018, 47(05):77-78+82.
5. 郭阳,臧埔,郜玉钢等. 化妆品防腐剂的使用现状及进展[J]. 中南药学, 2018, 16(09):1258-1263.
6. 杨娟,刘永龙,林芮等. 几种常用防腐剂对日化产品中腐败微生物抑制效果研究[J]. 工业微生物, 2016, 46(04):34-37.
7. 李欣航,张金龙,毕永贤,等. 无尼泊金酯类化妆品防腐体系的应用研究[J]. 日用化学品科学, 2018, 41(8):14-21.

反应信息

• 作为反应物：
  描述：

  己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯 在 氧气 、 copper(l) chloride 作用下， 以 二甲基亚砜 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 6.0h， 以74%的产率得到对苯醌
  参考文献：
  名称：

  通过连续的C–C键裂解 将羟基化合物逐步降解为醛†

  摘要：

  通过使用不带任何配体和添加剂的双金属催化体系（PdCl 2 + CuCl），通过C-C键的连续裂解将羟基化合物逐步降解为醛。广泛的适用性扩展到芳族，脂肪族，伯和仲醇以及木质素模型化合物的各种范围。

  DOI：

  10.1039/c8cc09504c
• 作为产物：
  描述：

  苯氧乙酸 在 ammonia borane 、 四氯化钛 作用下， 以 乙醚 为溶剂， 以96 %的产率得到己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯
  参考文献：
  名称：

  利用钛催化更安全地还原羧酸

  摘要：

  先前显示氨硼烷在回流下与羧酸反应形成伯酰胺，在催化 TiCl 4存在下在室温下将酸还原为醇。该方法能够耐受多种潜在反应性官能团，包括N-保护的氨基酸，可用于在酰胺、腈以及某种程度上酯存在的情况下选择性还原酸。在芳香酸存在下，可以选择性地还原脂肪酸。

  DOI：

  10.1021/acs.orglett.2c03326
• 作为试剂：
  描述：

  正癸烯 、 半胱胺盐酸盐 在 盐酸 、 己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯 、 aaph 作用下， 以 水 为溶剂， 以95%的产率得到2-(decylthio)ethaneamine hydrochloride
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING DTEA HCI
  [FR] PROCÉDÉ DE PRÉPARATION DE DTHEA HCI

  摘要：

  本发明提供了一种改进的方法，用于通过使用催化剂、溶剂和辅助反应的共溶剂，从癸烯和半胱氨酸盐酸盐制备DTEA HCl，并提供所得产物溶液的低温稳定化。

  公开号：

  WO2021216029A1

文献信息

• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。
• Quinolone-based compounds, formulations, and uses thereof
  申请人：Manetsch Roman

  公开号：US10000452B1

  公开（公告）日：2018-06-19

  Provided herein are quinolone-based compounds that can be used for treatment and/or prevention of malaria and formulations thereof. Also provided herein are methods of treating and/or preventing malaria in a subject by administering a quinolone-based compound or formulation thereof provided herein.

  本文提供了基于喹诺酮的化合物，可用于治疗和/或预防疟疾及其配方。本文还提供了通过给予本文提供的基于喹诺酮的化合物或配方来治疗和/或预防受试者疟疾的方法。
• PHOTOSENSITIVE RESIN COMPOSITION, OXIME SULFONATE COMPOUND, METHOD FOR FORMING CURED FILM, CURED FILM, ORGANIC EL DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE
  申请人：FUJIFILM Corporation

  公开号：US20130171415A1

  公开（公告）日：2013-07-04

  Disclosed is a photosensitive resin composition comprising: (Component A) an oxime sulfonate compound represented by Formula (1); (Component B) a resin comprising a constituent unit having an acid-decomposable group that is decomposed by an acid to form a carboxyl group or a phenolic hydroxy group; and (Component C) a solvent wherein in Formula (1) R 1 denotes an alkyl group, an aryl group, or a heteroaryl group, each R 2 independently denotes a hydrogen atom, an alkyl group, an aryl group, or a halogen atom, Ar 1 denotes an o-arylene group or an o-heteroarylene group, X denotes O or S, and n denotes 1 or 2, provided that of two or more R 2 s present in the compound, at least one denotes an alkyl group, an aryl group, or a halogen atom.

  揭示了一种光敏树脂组合物，包括：（组分A）由式（1）表示的肟磺酸盐化合物；（组分B）包括具有可被酸分解的基团的树脂，该基团通过酸分解形成羧基或酚羟基；和（组分C）溶剂 其中在式（1）中，R1表示烷基、芳基或杂芳基，每个R2独立地表示氢原子、烷基、芳基或卤素原子，Ar1表示邻芳撑基或邻杂芳撑基，X表示O或S，n表示1或2，前提是在化合物中存在两个或两个以上的R2时，至少有一个表示烷基、芳基或卤素原子。
• [EN] PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES<br/>[FR] INHIBITEURS DE JAK À BASE DE PYRIMIDINE POUR LE TRAITEMENT DE MALADIES DE LA PEAU
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2020219640A1

  公开（公告）日：2020-10-29

  The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory and autoimmune skin diseases.

  该发明提供了式(I)的化合物或其药用可接受盐，这些化合物是Janus激酶的抑制剂。该发明还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗炎症性和自身免疫性皮肤疾病的方法。
• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。

表征谱图